Tyson Foods, Inc. (TSN) Stock Price Today
Aura AI Summary
Key Stats
- $21.38BMarket Cap
- -Volume
- Consumer StaplesSector
- $68.7552W High
- $50.7252W Low
- -Typical Hold Time
- $28.96BEnterprise Value
- 3.36%Div Yield
- -Trading Activity
Track Tyson Foods, Inc. (TSN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Tyson Foods, Inc. has traded between a low of $50.72 and a high of $68.75, highlighting its annual price range. Buy and sell Tyson Foods, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Most Recent News
Global AI in Medical Coding market to reach $10.6B by 2035 with 13.5% CAGR, driven by healthcare digital transformation.
The global AI in Medical Coding market, valued at $3 billion in 2025, is projected to grow to $10.6 billion by 2035 at a 13.5% CAGR. Growth is fueled by increasing adoption of AI technologies in healthcare for automated coding, fraud detection, and r...
OMODA 4 debuts in Southeast Asia with AI cockpit tech, targeting young users and smart mobility growth.
OMODA & JAECOO launched the OMODA 4 SUV in Southeast Asia at the OMODA SUPER AI NIGHT event in Jakarta, showcasing its AI-powered cockpit technology integrated with ByteDance Seed large language model. The event highlighted the brand's strategy to ex...
AnaptysBio shifts to royalty management, focusing on growing Jemperli royalties from GSK.
AnaptysBio has transformed into a royalty management company centered on Jemperli, an oncology drug commercialized by GSK. The company now operates with minimal costs, targeting a 95% EBIT margin and holding over $140 million in net cash, eliminating...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.